Ashley W. Tiegs, M.D.. Xin Tao, Ph.D., Yiping Zhan, Ph.D., Christine Whitehead, R.N., Julia Kim, M.D., Brent Hanson, M.D., Emily Osman, M.D., Thomas J. Kim, M.D., George Patounakis, M.D., Ph.D., Jacqueline Gutmann, M.D., Arthur Castelbaum, M.D., Emre Seli, M.D., Chaim Jalas, Richard T. Scott Jr., M.D.
To determine the predictive value of an aneuploid diagnosis with a targeted next-generation sequencing–based preimplantation genetic testing for aneuploidy (PGT-A) assay in prognosticating the failure of a successful delivery.
Prospective, blinded, multicenter, nonselection study. All usable blastocysts were biopsied, and the single best morphologic blastocyst was transferred before genetic analysis. Preimplantation genetic testing for aneuploidy was performed after clinical outcome was determined. Clinical outcomes were compared to PGT-A results to calculate the predictive value of a PGT-A aneuploid diagnosis.
Couples undergoing their first in vitro fertilization cycle without recurrent pregnancy loss, antral follicle count < 8, or body mass index ≥ 35 kg/m2.
Main Outcome Measure(s)
The primary outcome was the ability of the analytical result of aneuploid to predict failure to deliver (clinical result). A secondary outcome was the impact of the trophectoderm biopsy on sustained implantation.
Four hundred two patients underwent 484 single, frozen, blastocyst transfers. The PGT-A aneuploid diagnosis clinical error rate was 0%. There was no difference in sustained implantation between the study group and an age-matched control group, where biopsy was not performed (47.9% vs. 45.8).
The PGT-A assay evaluated was highly prognostic of failure to deliver when an aneuploid result was obtained. Additionally, the trophectoderm biopsy had no detectable adverse impact on sustained implantation.
Clinical Trial Registration Numbers
NCT02032264 and NCT03604107.